Bluejay Diagnostics Completes Commercial-Scale IL-6 Antibody Production

TradingView
2025.12.30 14:23
portai
I'm PortAI, I can summarize articles.

On December 29, 2025, Bluejay Diagnostics, Inc. announced the completion of commercial-scale IL-6 antibody production. Key Highlights: Production includes both polyclonal and monoclonal antibodies.Antibodies meet internal criteria for clinical and commercial use.Inventory supports over nine million Symphony cartridges.Symphony™ system still requires regulatory clearance.Antibodies to aid in intellectual-property strategy development.Original SEC Filing: Bluejay Diagnostics, Inc. [ BJDX ] - 8-K - Dec. 30, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer